Ophthalmology is a highly dynamic space, impacted by social, demographic and regulatory factors that influence the direction and rate of clinical development. Halloran maintains a core team of consultants with specialized knowledge in the clinical development of ophthalmic products. This team has nearly 50 years of collective Phase 1 –3 clinical trial experience in both anterior (e.g., dry eye, uveitis, cataract, corneal diseases) and posterior (e.g., dry/wet age-related macular degeneration, Stargardt’ disease, diabetic retinopathy, glaucoma, retinitis pigmentosa) segment indications. Creating a positive impact for our clients is a core value at Halloran. Therefore, our ophthalmic clinical development team is constantly exploring ways to improve the quality of clinical study designs, shorten development timelines, and identify new technologies both for home-based and site-based monitoring of study assessments for our ophthalmology clients.